Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Targeted Therapy
100%
T-cell Leukemia/lymphoma
100%
North America
100%
Epigenetic Modification
100%
Lymphoma Cells
43%
BCL6
37%
P300
25%
Sigma Phase
25%
PARP Inhibitors (PARPi)
12%
Overall Survival
6%
Vulnerability
6%
Transcription Factor
6%
Lymphoma Biology
6%
Mature B Cells
6%
Chemorefractory Disease
6%
Human T-cell Leukemia Virus Type 1 (HTLV-1)
6%
Mature T Cells
6%
Olaparib
6%
Chemotherapy
6%
Japanese Population
6%
Achilles Heel
6%
Chromatin
6%
Sequence Analysis
6%
CD4+ T
6%
Therapeutic Targeting
6%
Lymphoma Patients
6%
Functional Aspects
6%
Dysregulated
6%
DNA Replication
6%
Novel Therapeutics
6%
Transcriptional Repressor
6%
Patient Cohort
6%
Targeted Exome Sequencing
6%
Mechanistic Basis
6%
Replication Program
6%
Gene mutation
6%
Epigenetics
6%
Targeted Treatment
6%
DNA Replication Stress
6%
Therapeutic Strategies
6%
NF-κB Signaling Pathway
6%
Specific Aims
6%
Gene Expression
6%
Medicine and Dentistry
Targeted Therapy
100%
Adult T-Cell Leukemia/Lymphoma
100%
Lymphoma Cell
25%
S Phase
25%
Lymphoma Cell Line
18%
DNA Synthesis
12%
Diseases
12%
Cell Cycle
6%
Overall Survival
6%
Human T-Lymphotropic Virus 1
6%
Gene Expression
6%
Exon
6%
PARP Inhibitor
6%
B Cell
6%
Olaparib
6%
T Cell Receptor
6%
Repressor Gene
6%
Epigenetic Modification
6%
T-Helper Cell
6%
Transcription Factors
6%
T Cell
6%
Signal Transduction
6%
Pathogenesis
6%
Chemotherapy
6%
Chromatin
6%
Biochemistry, Genetics and Molecular Biology
T Cell
100%
Targeted Therapy
100%
BCL6
33%
S Phase
22%
DNA Synthesis
11%
Exon
5%
Epigenetic Modification
5%
Overall Survival
5%
CD4
5%
Human T-Lymphotropic Virus 1
5%
T Cell Receptor
5%
Transcription
5%
Gene Expression
5%
Repressor
5%
Cell Cycle
5%
B Cell
5%
Transcription Factors
5%
Poly ADP Ribose Polymerase
5%
Chromatin
5%
Signal Transduction
5%